Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/72406
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Future long-term trials of postmenopausal hormone replacement therapy: what is possible and what is the optimal protocol and regimen?
Author: Purbrick, B.
Stranks, K.
Sum, C.
MacLennan, A.
Citation: Climacteric, 2012; 15(3):288-293
Publisher: Parthenon Publishing Group
Issue Date: 2012
ISSN: 1369-7137
1473-0804
Statement of
Responsibility: 
B. Purbrick, K. Stranks, C. Sum and A.H. MacLennan
Abstract: The ideal long-term, randomized, placebo-controlled trial of hormone replacement therapy (HRT) from near menopause for up to 30 years to assess major morbidity and mortality is impractical because of high cost, participant retention, therapy compliance, and continuity of research staff and funding. Also the trial regimen may become outdated. It is nihilistic to demand such a long-term trial before endorsing HRT. However, medium-term trials using surrogate measures for long-term morbidity and mortality are possible and two are near completion. If these studies have been able to maintain reasonable participant retention, therapy compliance and minimal breach of protocol, they will set standards for trials of new HRT regimens. This paper discusses lessons learnt from past attempts at long-term trials and suggests the currently optimal protocol and cost of assessing new HRT regimens to optimize potential benefi ts and minimize adverse effects. A 5-7 year randomized, placebo-controlled trial of a flexible transdermal estrogen regimen ± either a selective estrogen receptor modulator, e.g. bazedoxifene, or micronized progesterone is discussed. Mild to moderately symptomatic women, 1–4 years post menopause, can be recruited via general practice and group meetings. Future trials should be funded by independent agencies and are high priority in women’s health.
Keywords: Humans; Indoles; Progesterone; Selective Estrogen Receptor Modulators; Placebos; Estrogens; Estrogen Replacement Therapy; Administration, Cutaneous; Postmenopause; Research Design; Middle Aged; Women's Health; Female; Randomized Controlled Trials as Topic
Rights: © 2012 International Menopause Society
RMID: 0020119293
DOI: 10.3109/13697137.2011.635825
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.